.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Nanotechnology in oncology represents a transformative shift in modern cancer care. Traditional therapies frequently encounter significant limitations such as poor tumor selectivity and systemic toxicity. However, advanced nanoparticle-based strategies provide a promising solution. These platforms improve drug solubility and extend circulation time within the body. Consequently, they allow for more effective drug delivery directly to the malignant site.
Researchers utilize both passive and active mechanisms for tumor targeting. For instance, the enhanced permeability and retention (EPR) effect facilitates passive accumulation. Furthermore, active targeting employs specific ligands to bind to cancer cell receptors. This strategy enhances intracellular uptake significantly. Moreover, these approaches minimize the impact on healthy tissues. Therefore, patients often experience fewer side effects compared to traditional chemotherapy.
Despite immense preclinical potential, clinical translation remains difficult. Factors like patient-specific heterogeneity and regulatory hurdles contribute to high attrition rates. Additionally, some approved nanomedicines like Doxil and Abraxane have set a high standard. However, newer formulations sometimes fail to show consistent clinical benefits. Consequently, the medical community must focus on standardizing toxicological protocols and manufacturing processes. Ultimately, this integration aims to refine precision cancer therapy for better patient outcomes.
The enhanced permeability and retention (EPR) effect refers to the tendency of nanoparticles to accumulate in tumor tissue more than in normal tissues. This happens because tumor vessels are often leaky, and the lymphatic drainage is typically impaired. Consequently, this passive mechanism allows for higher drug concentrations at the cancer site.
Several nanomedicines have achieved clinical success. Specifically, liposomal doxorubicin (Doxil) and albumin-bound paclitaxel (Abraxane) are widely used. Furthermore, these formulations help reduce the severe side effects associated with their traditional, non-nanoparticle counterparts.
The main barriers include the significant variability in tumor types and patient-specific responses. Additionally, long-term toxicity concerns and complex manufacturing requirements often slow down the regulatory process. Therefore, bridging the gap between lab research and clinical practice requires more standardized protocols.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.
References
Fahim YA et al. Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment. Discov Nano. 2026 Jun 10. doi: undefined. PMID: 42268351.
Shi J et al. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2023.
Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2021.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Nanotechnology in oncology offers transformative drug delivery systems to improve selectivity and reduce toxicity. While preclinical results are strong, clinical translation faces hurdles like patient heterogeneity and regulatory barriers. This review explores synthesis methods and the future of precision therapy.
3 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
